Durability of Bivalent Boosters against Omicron Subvariants
- PMID: 37043647
- PMCID: PMC10120009
- DOI: 10.1056/NEJMc2302462
Durability of Bivalent Boosters against Omicron Subvariants
Figures
Similar articles
-
mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.bioRxiv [Preprint]. 2022 Nov 1:2022.10.31.514636. doi: 10.1101/2022.10.31.514636. bioRxiv. 2022. Update in: N Engl J Med. 2023 Jan 12;388(2):183-185. doi: 10.1056/NEJMc2214293 PMID: 36380757 Free PMC article. Updated. Preprint.
-
Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations.Vaccines (Basel). 2023 Apr 27;11(5):906. doi: 10.3390/vaccines11050906. Vaccines (Basel). 2023. PMID: 37243010 Free PMC article. Review.
-
Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.Microbiol Spectr. 2023 Mar 22;11(2):e0513122. doi: 10.1128/spectrum.05131-22. Online ahead of print. Microbiol Spectr. 2023. PMID: 36946738 Free PMC article.
-
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.Nat Commun. 2023 Sep 27;14(1):6041. doi: 10.1038/s41467-023-41678-9. Nat Commun. 2023. PMID: 37758707 Free PMC article.
-
The Omicron-transformer: Rise of the subvariants in the age of vaccines.Ann Acad Med Singap. 2022 Nov;51(11):712-729. doi: 10.47102/annals-acadmedsg.2022294. Ann Acad Med Singap. 2022. PMID: 36453218 Review.
Cited by
-
Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022-August 2023.Influenza Other Respir Viruses. 2024 Nov;18(11):e70027. doi: 10.1111/irv.70027. Influenza Other Respir Viruses. 2024. PMID: 39496339 Free PMC article.
-
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity.Sci Transl Med. 2024 Oct 23;16(770):eadp8920. doi: 10.1126/scitranslmed.adp8920. Epub 2024 Oct 23. Sci Transl Med. 2024. PMID: 39441905 Free PMC article.
-
Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.Geroscience. 2024 Oct 12. doi: 10.1007/s11357-024-01346-2. Online ahead of print. Geroscience. 2024. PMID: 39395130
-
Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge.bioRxiv [Preprint]. 2024 Sep 13:2024.09.12.612598. doi: 10.1101/2024.09.12.612598. bioRxiv. 2024. PMID: 39372768 Free PMC article. Preprint.
-
Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023.Euro Surveill. 2024 Sep;29(37):2300587. doi: 10.2807/1560-7917.ES.2024.29.37.2300587. Euro Surveill. 2024. PMID: 39268649 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources